No Data
Capital Allocation Trends At Mega Genomics (HKG:6667) Aren't Ideal
Mei Yin Genetics (06667.HK) spent 0.0445 million HKD to repurchase 5,800 shares on December 27.
Gelonghui reported on December 27 that Meiyin Gene (06667.HK) announced that on December 27, it spent 0.0445 million Hong Kong dollars to repurchase 5,800 shares.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
On December 19, Meian Genetics (06667) spent approximately 1.2118 million Hong Kong dollars to repurchase 0.1578 million shares.
Mei Yin Genetics (06667) announced that on December 19, 2024, approximately 1.2118 million Hong Kong dollars will be spent to repurchase 15...
On December 18, Meigen Gene (06667.HK) spent 1.419 million HKD to repurchase 0.184 million shares.
Gelonghui, December 18 - Meiyin Gene (06667.HK) announced that on December 18, it spent 1.419 million Hong Kong dollars to repurchase 0.184 million shares.
Mei Yin Genetics (06667.HK) spent HKD 0.595 million to repurchase 0.0772 million shares on December 17.
Gelonghui reported on December 17 that Meiyin Gene (06667.HK) announced the repurchase of 0.0772 million shares at a cost of 0.595 million Hong Kong dollars on December 17.
No Data